Sign in

    Harrison Parsons • Stephens

    Harrison Parsons's questions to Cytek Biosciences Inc (CTKB) leadership

    Harrison Parsons's questions to Cytek Biosciences Inc (CTKB) leadership • Q2 2025

    Question

    Harrison Parsons from Stephens Inc. asked about the expected revenue contribution and margin profile of the new Aurora EVO and MUSE Micro systems, and whether current guidance assumes the recent high growth rates in reagents and services will continue.

    Answer

    CFO William McCombe explained that the high-ASP Aurora EVO would be the larger revenue contributor and supportive of margins, while the low-priced MUSE Micro would not have a significant margin impact. While not guiding specific product lines, he stated that the underlying drivers for service (installed base growth) and reagent growth (execution, product range) remain strong and should continue to produce similar results.

    Ask Fintool Equity Research AI

    Harrison Parsons's questions to Cytek Biosciences Inc (CTKB) leadership • Q4 2024

    Question

    Harrison Parsons from Stephens Inc., on for Mason, asked about the underlying assumptions for flow cytometry market growth embedded in the 2025 revenue guidance and requested color on expected growth trends across key geographies.

    Answer

    CFO William McCombe stated they assumed no significant change from 2024's market conditions, which they saw as mildly negative for instruments, and factored in near-term headwinds, resulting in a back-end loaded growth profile. He expects a continuation of 2024's geographic trends, with a flattish U.S. market and better growth from APAC and EMEA.

    Ask Fintool Equity Research AI

    Harrison Parsons's questions to Hologic Inc (HOLX) leadership

    Harrison Parsons's questions to Hologic Inc (HOLX) leadership • Q3 2025

    Question

    Harrison Parsons, on for Mason Carrico, asked about the benefits seen from selling Endomagnetics through the direct sales force and the early results of the commercial reorganization in Breast Health.

    Answer

    CEO Stephen MacMillan highlighted the success of the direct sales model for Endomagnetics, citing its nearly $20 million in quarterly revenue. He also noted the bifurcated sales force helped drive 6% organic growth in the broader interventional line. CFO Karleen Oberton added that the commercial reorg is showing positive early traction without the typical disruption.

    Ask Fintool Equity Research AI

    Harrison Parsons's questions to Pacific Biosciences of California Inc (PACB) leadership

    Harrison Parsons's questions to Pacific Biosciences of California Inc (PACB) leadership • Q1 2025

    Question

    Harrison Parsons of Stephens inquired about the visibility into the Vega sales funnel and asked about the assumptions and potential risks for Revio's consumable pull-through within the 2025 guidance.

    Answer

    Christian Henry, President and CEO, expressed reasonable confidence in the Vega funnel, noting its lower cost generates more sales opportunities. For Revio pull-through, he explained the guidance is conservative, treating large projects as potential upside and assuming a pull-through in the low-to-mid $200,000s range. Key risks cited were China tariffs and NIH budget cuts.

    Ask Fintool Equity Research AI